
Pfizer head joins UK biotech Calchan
pharmafile | May 19, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |ย ย Pfizer, calhan, zahid aliย
UK-based biotech Calchan has looked to Pfizer for appointing a new chief scientific officer in Zahid Ali.
Ali has almost two decades of industry experience with pharma companies, from leading programmes across drug development and clinical studies, to working with the commercial teams to identify new product strategies.
Most recently he was a senior director of clinical research at Pfizer where he was responsible for a number of early clinical development programmes focused on pain research.
He started his career as a senior research pharmacologist at Merckโs UK neuroscience centre, before taking up senior positions at GlaxoSmithKline which included being a director of its discovery medicine unit.
Brenda Reynolds who is the chief executive of Calchan says: โZahid Aliโs appointment is an important one as we continue to assemble a strong team to develop our assets at Calchan. I am delighted that Zahid has chosen to join us as his considerable experience and background, notably as a clinical director at Pfizer, will be invaluable.โ
Ali adds: โI am very excited to be joining Calchan, which has a management team of enviable experience and a very successful track record in the sector.โ
Related Content
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






